$NRXP
NRX Pharmaceuticals, Inc.

2021 Q4 Form 10-K Financial Statement

#000155837022004899 Filed on March 31, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $46.56M $74.94M $437.8K
YoY Change 10534.92% 8159.11% 130.43%
% of Gross Profit
Research & Development $6.413M $20.26M
YoY Change 90.65%
% of Gross Profit
Depreciation & Amortization $390.00 $2.000K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $52.98M $115.8M $437.8K
YoY Change 11999.76% 125.34% 130.43%
Operating Profit -$115.8M
YoY Change 125.34%
Interest Expense $481.3K $18.00K -$655.0K
YoY Change -173.47% -67.86% -485.29%
% of Operating Profit
Other Income/Expense, Net $21.70M $22.73M
YoY Change -5928.97%
Pretax Income -$30.79M -$93.06M -$1.093M
YoY Change 2717.79% 79.74% 5364.05%
Income Tax $0.00 $0.00 -$5.360K
% Of Pretax Income
Net Earnings -$30.79M -$93.06M -$1.087M
YoY Change 2731.68% 79.74% 10774.5%
Net Earnings / Revenue
Basic Earnings Per Share -$1.98
Diluted Earnings Per Share -$532.8K -$1.98 -$404.6K
COMMON SHARES
Basic Shares Outstanding 58.81M 46.92M
Diluted Shares Outstanding 46.92M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.61M $27.61M $470.00
YoY Change 5873304.26% 5873304.26%
Cash & Equivalents $27.61M $1.859M
Short-Term Investments
Other Short-Term Assets $5.109M $5.109M $26.00K
YoY Change 19550.0% 6131.25% -62.86%
Inventory
Prepaid Expenses $30.35K
Receivables $831.0K
Other Receivables
Total Short-Term Assets $32.71M $32.71M $2.930M
YoY Change 1016.52% 39572.57% 4085.71%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.968M
YoY Change -81.36%
Other Assets $15.00K $15.00K $11.00K
YoY Change 36.36%
Total Long-Term Assets $15.00K $15.00K $11.00K
YoY Change 36.36% -99.75% -99.97%
TOTAL ASSETS
Total Short-Term Assets $32.71M $32.71M $2.930M
Total Long-Term Assets $15.00K $15.00K $11.00K
Total Assets $32.73M $32.73M $2.941M
YoY Change 1012.85% 440.94% -90.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.687M $3.687M $3.153M
YoY Change 16.94% 504.91% 408.55%
Accrued Expenses $2.375M $1.632M $1.729M
YoY Change 37.36%
Deferred Revenue $292.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $518.0K $518.0K
YoY Change
Total Short-Term Liabilities $11.92M $11.92M $46.16M
YoY Change -74.17% 1856.16% 7345.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $2.672M
YoY Change -100.0% -100.0% 37.03%
Other Long-Term Liabilities $655.1K
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $3.327M
YoY Change -100.0% -100.0% 70.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.92M $11.92M $46.16M
Total Long-Term Liabilities $0.00 $0.00 $3.327M
Total Liabilities $11.92M $11.92M $46.71M
YoY Change -74.48% 202.87% 1717.59%
SHAREHOLDERS EQUITY
Retained Earnings -$183.2M -$90.18M
YoY Change 103.2%
Common Stock $59.00K $43.00K
YoY Change 37.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.81M $20.81M -$43.77M
YoY Change
Total Liabilities & Shareholders Equity $32.73M $32.73M $2.941M
YoY Change 1012.85% 440.94% -90.83%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$30.79M -$93.06M -$1.087M
YoY Change 2731.68% 79.74% 10774.5%
Depreciation, Depletion And Amortization $390.00 $2.000K
YoY Change 0.0%
Cash From Operating Activities -$11.28M -$37.70M -$227.1K
YoY Change 4867.81% 1564.59% -12.67%
INVESTING ACTIVITIES
Capital Expenditures -$390.00 -$7.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$33.17K
YoY Change -100.34%
Cash From Investing Activities -$390.00 -$7.000K -$33.17K
YoY Change -98.82% 250.0% -100.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.230K 63.46M 220.7K
YoY Change -99.44% 1853.09% -102.31%
NET CHANGE
Cash From Operating Activities -11.28M -37.70M -227.1K
Cash From Investing Activities -390.0 -7.000K -33.17K
Cash From Financing Activities 1.230K 63.46M 220.7K
Net Change In Cash -11.28M 25.75M -39.56K
YoY Change 28411.27% 2521.79% -78.02%
FREE CASH FLOW
Cash From Operating Activities -$11.28M -$37.70M -$227.1K
Capital Expenditures -$390.00 -$7.000K
Free Cash Flow -$11.28M -$37.70M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46917701
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34270955
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001719406
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021 dei Entity Registrant Name
EntityRegistrantName
NRX Pharmaceuticals, Inc.
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42973462
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58810550
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.98
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2021 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-7.44
CY2020 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.51
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
831000
CY2021 dei City Area Code
CityAreaCode
484
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5109000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
240000
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19801
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-38302
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2844431
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
1201 Orange Street
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Wilmington
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
DE
CY2021 dei Local Phone Number
LocalPhoneNumber
254-6134
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
187300000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
66641314
CY2021Q4 us-gaap Cash
Cash
27605000
CY2020Q4 us-gaap Cash
Cash
1859000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
257000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
32714000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
2930000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11000
CY2021Q4 us-gaap Assets
Assets
32729000
CY2020Q4 us-gaap Assets
Assets
2941000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3687000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3153000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2375000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1729000
CY2021Q4 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
469000
CY2020Q4 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
1547000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
4582000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
292000
CY2021Q4 nrxp Notes Payable And Accrued Interest Current
NotesPayableAndAccruedInterestCurrent
518000
CY2020Q4 nrxp Notes Payable And Accrued Interest Current
NotesPayableAndAccruedInterestCurrent
249000
CY2020Q4 nrxp Accrued Settlement Expense
AccruedSettlementExpense
39486000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11923000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
46164000
CY2020Q4 nrxp Notes Payable And Accrued Interest Non Current
NotesPayableAndAccruedInterestNonCurrent
548000
CY2021Q4 us-gaap Liabilities
Liabilities
11923000
CY2020Q4 us-gaap Liabilities
Liabilities
46712000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58810550
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42973462
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
59000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
43000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
203990000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
46366000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183243000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90180000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20806000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-43771000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32729000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2941000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20257000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10625000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
74944000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11436000
CY2021 nrxp Settlement Expense
SettlementExpense
21366000
CY2020 nrxp Settlement Expense
SettlementExpense
39486000
CY2021 nrxp Expense Reimbursement
ExpenseReimbursement
771000
CY2020 nrxp Expense Reimbursement
ExpenseReimbursement
10160000
CY2021 us-gaap Operating Expenses
OperatingExpenses
115796000
CY2020 us-gaap Operating Expenses
OperatingExpenses
51387000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-115796000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-51387000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
121000
CY2021 us-gaap Interest Expense
InterestExpense
18000
CY2020 us-gaap Interest Expense
InterestExpense
56000
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1692000
CY2021 nrxp Gain Loss On Fair Value Of Cash Earn Out Liability
GainLossOnFairValueOfCashEarnOutLiability
20938000
CY2020 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-27000
CY2020 nrxp Gain Loss On Conversion Of Debt
GainLossOnConversionOfDebt
-307000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22733000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-390000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-93063000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-51777000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-93063000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-51777000
CY2021 nrxp Deemed Dividend Warrants
DeemedDividendWarrants
2692000
CY2021 nrxp Deemed Dividend Earnout Shares
DeemedDividendEarnoutShares
253130000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-348885000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-51777000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.98
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2021 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-7.44
CY2020 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.51
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46917701
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34270955
CY2019Q4 nrxp Stockholders Equity As Previously Reported
StockholdersEquityAsPreviouslyReported
-4851000
CY2019Q4 nrxp Retroactive Application Of Reverse Recapitalization Value
RetroactiveApplicationOfReverseRecapitalizationValue
8000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-4843000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2579000
CY2020 nrxp Convertible Preferred Stock Value Issued
ConvertiblePreferredStockValueIssued
50000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3962000
CY2020 nrxp Stock Issued During Period Value To Settle Accounts Payable
StockIssuedDuringPeriodValueToSettleAccountsPayable
145000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5383000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
730000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-51777000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-43771000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9624000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
60852000
CY2021 nrxp Net Of Redemptions And Issuance Costs
NetOfRedemptionsAndIssuanceCosts
1413000
CY2021 nrxp Stock Repurchased During Period Value Merger And Recapitalization Net Of Redemptions And Issuance Costs
StockRepurchasedDuringPeriodValueMergerAndRecapitalizationNetOfRedemptionsAndIssuanceCosts
26616000
CY2021 nrxp Financing Net Of Issuance Costs
FinancingNetOfIssuanceCosts
1900000
CY2021 nrxp Stock Issued During Period Value New Issues From Private Investment In Equity
StockIssuedDuringPeriodValueNewIssuesFromPrivateInvestmentInEquity
8100000
CY2021 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
4850000
CY2021 nrxp Adjustments To Additional Paid In Capital Modifications Of Stock Options Due To Business Combination
AdjustmentsToAdditionalPaidInCapitalModificationsOfStockOptionsDueToBusinessCombination
1015000
CY2021 nrxp Adjustments To Additional Paid In Capital Modifications Of Warrant Issued Due To Business Combination
AdjustmentsToAdditionalPaidInCapitalModificationsOfWarrantIssuedDueToBusinessCombination
2330000
CY2021 nrxp Sale Of Stock And Warrants Issuance Costs
SaleOfStockAndWarrantsIssuanceCosts
2641000
CY2021 nrxp Common Stock And Warrants Issued In Private Placement Net Of Issuance Costs
CommonStockAndWarrantsIssuedInPrivatePlacementNetOfIssuanceCosts
27359000
CY2021 nrxp Issuance Of Stock For Exercise Of Warrants And Option
IssuanceOfStockForExerciseOfWarrantsAndOption
16699000
CY2021 nrxp Stock Issued For Payment Of Consulting Services
StockIssuedForPaymentOfConsultingServices
48987000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4440000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-93063000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20806000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-93063000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-51777000
CY2021 us-gaap Depreciation
Depreciation
2000
CY2020 us-gaap Depreciation
Depreciation
2000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
7785000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
730000
CY2020 nrxp Non Cash Warrant Issuance Expenses
NonCashWarrantIssuanceExpenses
5383000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
121000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1692000
CY2021 nrxp Gain Loss On Fair Value Of Cash Earnout Liability
GainLossOnFairValueOfCashEarnoutLiability
20938000
CY2020 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-27000
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
17000
CY2021 us-gaap Paid In Kind Interest
PaidInKindInterest
19000
CY2020 us-gaap Paid In Kind Interest
PaidInKindInterest
65000
CY2021 nrxp Noncash Settlement Expense
NoncashSettlementExpense
21366000
CY2020 nrxp Noncash Settlement Expense
NoncashSettlementExpense
39486000
CY2021 nrxp Non Cash Consulting Expense
NonCashConsultingExpense
53837000
CY2020 nrxp Loss On Common Stock Issued To Settle Accounts Payable
LossOnCommonStockIssuedToSettleAccountsPayable
42000
CY2020 nrxp Gain Loss On Conversion Of Debt
GainLossOnConversionOfDebt
-307000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-831000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
831000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4809000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
143000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-19000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1183000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-901000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3244000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37703000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2265000
CY2021 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
7000
CY2020 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
2000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
620000
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
50000
CY2021 nrxp Proceeds From Issuance Of Common Stock And Exercise Of Stock Options
ProceedsFromIssuanceOfCommonStockAndExerciseOfStockOptions
9624000
CY2020 nrxp Proceeds From Issuance Of Common Stock And Exercise Of Stock Options
ProceedsFromIssuanceOfCommonStockAndExerciseOfStockOptions
2579000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
16699000
CY2021 nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
27359000
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
11050000
CY2021 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-1100000
CY2021 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-176000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63456000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3249000
CY2021 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
25746000
CY2020 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
982000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1859000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
877000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27605000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1859000
CY2021 nrxp Reclassification Of Settlement Liability Upon Issuance Of Warrant
ReclassificationOfSettlementLiabilityUponIssuanceOfWarrant
60852000
CY2021 nrxp Issuance Of Common Stock Warrants As Offering Costs
IssuanceOfCommonStockWarrantsAsOfferingCosts
1027000
CY2020 nrxp Issuance Of Common Stock Warrants As Offering Costs
IssuanceOfCommonStockWarrantsAsOfferingCosts
31000
CY2021 nrxp Extinguishment Of Paycheck Protection Program Loan
ExtinguishmentOfPaycheckProtectionProgramLoan
121000
CY2020 us-gaap Stock Issued1
StockIssued1
3655000
CY2020 nrxp Common Stock Issued To Settle Accounts Payable
CommonStockIssuedToSettleAccountsPayable
145000
CY2021Q4 us-gaap Cash
Cash
27600000
CY2021 nrxp Shares Of Stock Issued For Exercise Of Warrants And Options
SharesOfStockIssuedForExerciseOfWarrantsAndOptions
3830586
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
16700000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of common and preferred stock, stock options, warrants, and Earnout Cash liability. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk and Off-Balance Sheet Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash is the only financial instrument that is potentially subject to concentrations of credit risk. The Company’s cash is deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held. The Company has no financial instruments with off-balance sheet risk of loss.</p>
CY2021 nrxp Deemed Dividend Earnout Shares
DeemedDividendEarnoutShares
253100000
CY2021 nrxp Option Exchange Ratio Shares Earnout Shares For Common Stockholders
OptionExchangeRatioSharesEarnoutSharesForCommonStockholders
22209280
CY2021 nrxp Option Exchange Ratio Value Earnout Cash For Common Stockholders
OptionExchangeRatioValueEarnoutCashForCommonStockholders
88800000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
3224000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
49000
CY2021Q4 nrxp Prepaid Manufacturing Expenses Current
PrepaidManufacturingExpensesCurrent
1028000
CY2021Q4 nrxp Prepaid Clinical Development Expenses
PrepaidClinicalDevelopmentExpenses
512000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
345000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
165000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
26000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5109000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
240000
CY2021Q4 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1055000
CY2020Q4 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
586000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
743000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
531000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
456000
CY2021Q4 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
113000
CY2020Q4 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
5000
CY2021Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
8000
CY2020Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
607000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2375000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1729000
CY2020Q1 us-gaap Common Unit Issuance Value
CommonUnitIssuanceValue
10000000.0
CY2020Q1 nrxp Fair Value Of Performance Shares Granted Per Share
FairValueOfPerformanceSharesGrantedPerShare
10.63
CY2020Q1 nrxp Accrued Interest
AccruedInterest
400000
CY2020Q1 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
132739
CY2020Q1 nrxp Discounted Stock Price Per Share
DiscountedStockPricePerShare
2.78
CY2020 nrxp Common Stock Fair Value Outstanding
CommonStockFairValueOutstanding
300000
CY2020Q2 us-gaap Debt Instrument Term
DebtInstrumentTerm
P2Y
CY2020Q2 us-gaap Debt Instrument Description
DebtInstrumentDescription
The PPP Loan amount may be eligible for forgiveness in the event that (1) at least 75% of the PPP Loan proceeds are used to cover payroll costs and the remainder is used for mortgage interest, rent and utility costs over the eight-week period after the PPP Loan is made, and (2) the number of employees and compensation levels are generally maintained.
CY2021 nrxp Outstanding Principal Written Off
OutstandingPrincipalWrittenOff
100000
CY2021 nrxp Outstanding Accrued And Unpaid Interest Written Off
OutstandingAccruedAndUnpaidInterestWrittenOff
100000
CY2021Q4 nrxp Carrying Value Of Issued Notes
CarryingValueOfIssuedNotes
-500000
CY2020Q4 nrxp Carrying Value Of Issued Notes
CarryingValueOfIssuedNotes
-774000
CY2021Q4 nrxp Accrued Interest
AccruedInterest
18000
CY2020Q4 nrxp Accrued Interest
AccruedInterest
23000
CY2021 nrxp Conversion Of Notes Payable And Accrued Interest
ConversionOfNotesPayableAndAccruedInterest
518000
CY2020 nrxp Conversion Of Notes Payable And Accrued Interest
ConversionOfNotesPayableAndAccruedInterest
797000
CY2021Q4 nrxp Notes Payable And Accrued Interest Current
NotesPayableAndAccruedInterestCurrent
518000
CY2020Q4 nrxp Notes Payable And Accrued Interest Current
NotesPayableAndAccruedInterestCurrent
249000
CY2020Q4 nrxp Notes Payable And Accrued Interest Non Current
NotesPayableAndAccruedInterestNonCurrent
548000
CY2021 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2020 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2021Q1 nrxp Settlement Expense
SettlementExpense
21400000
CY2021Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1833596
CY2021Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9200000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
516025
CY2021Q3 nrxp Contingent Earnout Shares Excluded From Eps Computation
ContingentEarnoutSharesExcludedFromEpsComputation
185472
CY2021 nrxp Issuance Of Stock For Exercise Of Warrants And Option
IssuanceOfStockForExerciseOfWarrantsAndOption
16700000
CY2021 nrxp Shares Of Stock Issued For Payment Of Consulting Services
SharesOfStockIssuedForPaymentOfConsultingServices
4834045
CY2020 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
1138199
CY2020 nrxp Gain Loss On Conversion Of Debt
GainLossOnConversionOfDebt
-300000
CY2020 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
30020
CY2020 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
100000
CY2020 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
100000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3075470
CY2020 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P4Y4M2D
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.09
CY2020Q4 nrxp Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
150956000
CY2021 nrxp Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
6193449
CY2021 nrxp Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
P1Y10M24D
CY2021 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
4.62
CY2021 nrxp Class Of Warrant Or Right Granted Intrinsic Value
ClassOfWarrantOrRightGrantedIntrinsicValue
115941000
CY2021 nrxp Class Of Warrant Or Right Assumed
ClassOfWarrantOrRightAssumed
3586250
CY2021 nrxp Class Of Warrant Or Rights Assumed In Period Weighted Average Remaning Contractual Term
ClassOfWarrantOrRightsAssumedInPeriodWeightedAverageRemaningContractualTerm
P5Y
CY2021 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Assumed
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAssumed
11.50
CY2021 nrxp Class Of Warrant Or Right Assumed Intrinsic Value
ClassOfWarrantOrRightAssumedIntrinsicValue
45725000
CY2021 nrxp Warrants Exercised During Period
WarrantsExercisedDuringPeriod
3330956
CY2021 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Assumed Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAssumedExercised
3.19
CY2021 nrxp Warrants Exercised Aggregate Intrinsic Value
WarrantsExercisedAggregateIntrinsicValue
67412000
CY2021 nrxp Class Of Warrant Or Right Forfeited
ClassOfWarrantOrRightForfeited
218423
CY2021 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Cancelled
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled
1.53
CY2021 nrxp Warrants Canceled Or Forfeited Aggregate Intrinsic Value
WarrantsCanceledOrForfeitedAggregateIntrinsicValue
1501000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9305790
CY2021 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P3Y7M13D
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.09
CY2021Q4 nrxp Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
4942000
CY2021Q4 nrxp Number Of Units Outstanding
NumberOfUnitsOutstanding
600000
CY2021Q4 nrxp Unit Price
UnitPrice
10.00
CY2021 nrxp Embedded Derivative Liability Expected Dividend Yield
EmbeddedDerivativeLiabilityExpectedDividendYield
0
CY2021Q4 nrxp Aggregate Exercise Price
AggregateExercisePrice
6000000.0
CY2021Q3 nrxp Number Of Units Outstanding
NumberOfUnitsOutstanding
600000
CY2021Q3 nrxp Number Of Shares Of Common Stock Created In Conversion
NumberOfSharesOfCommonStockCreatedInConversion
499630
CY2021 nrxp Number Of Shares Per Right
NumberOfSharesPerRight
1
CY2021 nrxp Fractional Shares Issued Upon Conversion Of Rights
FractionalSharesIssuedUponConversionOfRights
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0069
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0145
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0079
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.800
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2414303
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.17
CY2020 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
53660000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1004883
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
2.25
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y2M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
3056000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.57
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.80
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
31100000
CY2021Q4 nrxp Allocated Share Based Compensation Expense Expected To Be Recognized In Future
AllocatedShareBasedCompensationExpenseExpectedToBeRecognizedInFuture
6600000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y25D
CY2021Q4 nrxp Strike Price
StrikePrice
11.50
CY2020Q4 nrxp Strike Price
StrikePrice
11.50
CY2021 nrxp Warrant Liability Fair Value Assumptions Expected Term
WarrantLiabilityFairValueAssumptionsExpectedTerm
P4Y4M24D
CY2020 nrxp Warrant Liability Fair Value Assumptions Expected Term
WarrantLiabilityFairValueAssumptionsExpectedTerm
P4Y10M24D
CY2021 nrxp Warrant Liability Fair Value Assumptions Expected Volatility Rate
WarrantLiabilityFairValueAssumptionsExpectedVolatilityRate
0.828
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7785000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
730000
CY2020 nrxp Warrant Liability Fair Value Assumptions Expected Volatility Rate
WarrantLiabilityFairValueAssumptionsExpectedVolatilityRate
0.357
CY2021 nrxp Warrant Liability Fair Value Assumptions Risk Free Interest Rate
WarrantLiabilityFairValueAssumptionsRiskFreeInterestRate
0.0117
CY2020 nrxp Warrant Liability Fair Value Assumptions Risk Free Interest Rate
WarrantLiabilityFairValueAssumptionsRiskFreeInterestRate
0.0085
CY2021Q4 nrxp Fair Value Of Warrants
FairValueOfWarrants
2.14
CY2020Q4 nrxp Fair Value Of Warrants
FairValueOfWarrants
3.78
CY2021 nrxp Estimated Trading Price
EstimatedTradingPrice
24.25
CY2021 nrxp Deemed Dividend Earnout Shares
DeemedDividendEarnoutShares
253100000
CY2021 nrxp Net Impact To Additional Paid In Capital
NetImpactToAdditionalPaidInCapital
0
CY2021Q4 us-gaap Share Price
SharePrice
4.78
CY2020Q4 us-gaap Share Price
SharePrice
11.62
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.0005
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.0004
CY2021 nrxp Effective Income Tax Rate Reconciliation Fair Market Value Earnout
EffectiveIncomeTaxRateReconciliationFairMarketValueEarnout
-0.0472
CY2021 nrxp Effective Income Tax Rate Reconciliation Settlement Warrants
EffectiveIncomeTaxRateReconciliationSettlementWarrants
0.1335
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0002
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0001
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0005
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0174
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.1262
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.2301
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0013
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0024
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-11709000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-11016000
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-5000
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
3000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-42000
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-901000
CY2021 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
11756000
CY2020 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
11914000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
28053000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8244000
CY2021Q4 nrxp Deferred Tax Assets Common Stock Warrants
DeferredTaxAssetsCommonStockWarrants
1876000
CY2020Q4 nrxp Deferred Tax Assets Common Stock Warrants
DeferredTaxAssetsCommonStockWarrants
1406000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
134000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
128000
CY2020Q4 nrxp Deferred Tax Assets Share Options
DeferredTaxAssetsShareOptions
469000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1584000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
681000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
100000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
121000
CY2020Q4 nrxp Deferred Tax Assets Settlement Of Liability
DeferredTaxAssetsSettlementOfLiability
9006000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
59000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
500000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
375000
CY2021Q4 nrxp Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
2000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
32245000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
20489000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
32245000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20489000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021 nrxp Unrecognized Tax Benefits Decrease In Deferred Tax Asset
UnrecognizedTaxBenefitsDecreaseInDeferredTaxAsset
500000
CY2021Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
100000
CY2020Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
100000
CY2021 dei Auditor Name
AuditorName
KPMG LLP
CY2021 dei Auditor Location
AuditorLocation
Short Hills, NJ
CY2021 dei Auditor Firm
AuditorFirmId
185

Files In Submission

Name View Source Status
0001558370-22-004899-index-headers.html Edgar Link pending
0001558370-22-004899-index.html Edgar Link pending
0001558370-22-004899.txt Edgar Link pending
0001558370-22-004899-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrxp-20211231.xsd Edgar Link pending
nrxp-20211231x10k.htm Edgar Link pending
nrxp-20211231x10k001.jpg Edgar Link pending
nrxp-20211231x10k002.jpg Edgar Link pending
nrxp-20211231x10k003.jpg Edgar Link pending
nrxp-20211231x10k004.jpg Edgar Link pending
nrxp-20211231x10k005.jpg Edgar Link pending
nrxp-20211231x10k006.jpg Edgar Link pending
nrxp-20211231x10k007.jpg Edgar Link pending
nrxp-20211231x10k008.jpg Edgar Link pending
nrxp-20211231x10k009.jpg Edgar Link pending
nrxp-20211231x10k010.jpg Edgar Link pending
nrxp-20211231x10k011.jpg Edgar Link pending
nrxp-20211231x10k012.jpg Edgar Link pending
nrxp-20211231x10k013.jpg Edgar Link pending
nrxp-20211231x10k014.jpg Edgar Link pending
nrxp-20211231x10k015.jpg Edgar Link pending
nrxp-20211231x10k016.jpg Edgar Link pending
nrxp-20211231x10k017.jpg Edgar Link pending
nrxp-20211231x10k018.jpg Edgar Link pending
nrxp-20211231x10k_htm.xml Edgar Link completed
nrxp-20211231xex10d46.htm Edgar Link pending
nrxp-20211231xex10d46001.jpg Edgar Link pending
nrxp-20211231xex10d46002.jpg Edgar Link pending
nrxp-20211231xex10d46003.jpg Edgar Link pending
nrxp-20211231xex31d1.htm Edgar Link pending
nrxp-20211231xex31d2.htm Edgar Link pending
nrxp-20211231xex32d1.htm Edgar Link pending
nrxp-20211231xex32d2.htm Edgar Link pending
nrxp-20211231_cal.xml Edgar Link unprocessable
nrxp-20211231_def.xml Edgar Link unprocessable
nrxp-20211231_lab.xml Edgar Link unprocessable
nrxp-20211231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending